<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968472</url>
  </required_header>
  <id_info>
    <org_study_id>LXUN</org_study_id>
    <nct_id>NCT02968472</nct_id>
  </id_info>
  <brief_title>A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia</brief_title>
  <official_title>Single Center, Open, Phase I Clinical Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First People's Hospital of Yunnan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen Geno-Immune Medical Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First People's Hospital of Yunnan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A chimeric antigen receptor gene-modified T cells (CART: 4SCAR19)by targeted the CD19&#xD;
      (cluster of differentiation antigen 19), treat patients with CD19 positive malignant B cells&#xD;
      tumor, assess treatment safety, and observe therapeutic effects. At the same time,the change&#xD;
      process of the CART and residual tumor status of the patient are observe dynamicallyï¼Œ which&#xD;
      summarizes the best therapeutic effect.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Using CTCAE 4 standard to evaluate the level of adverse events after receiving the cells.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Safety of fourth generation anti CD19 CAR-T cells in patients with relapsed and refractory B-ALL - Using CTCAE 4 standard to evaluate the level of adverse events after receiving the cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti tumor activity of fourth generation anti CD19 CAR-T cells in patients with relapsed or refractory B-ALL (B cell acute lymphoblastic leukemia)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>B Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>prophylactic 4SCAR19 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>prophylactic 4SCAR19 cells</intervention_name>
    <description>Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19</description>
    <arm_group_label>prophylactic 4SCAR19 cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients aged more than 6 months.&#xD;
&#xD;
          -  the immune phenotype analysis of patients with malignant B cell surface expression&#xD;
             CD19 molecules.&#xD;
&#xD;
          -  the Karnofsky performance status score over 80 points, is expected to patients&#xD;
             survival time is more than 3 months.&#xD;
&#xD;
          -  the important viscera function meet: heart ultrasound tip heart ejection fraction 50%&#xD;
             or higher, electrocardiogram (ecg) not seen obvious abnormality;The blood oxygen&#xD;
             saturation 90% or higher;Creatinine 2.5 times normal range or less; aspartate&#xD;
             aminotransferase and aspartate aminotransferase3 times normal range or less, total&#xD;
             bilirubin of 2.0 mg/dl or less.&#xD;
&#xD;
          -  or greater Hgb 80 g/L.&#xD;
&#xD;
          -  no contraindications to solid and cell separation&#xD;
&#xD;
          -  the patient and family to have a strong willingness to participate in clinical trials,&#xD;
             and are willing to bear all the consequence caused by the test failed, and sign the&#xD;
             informed consent.&#xD;
&#xD;
          -  the panel discussion, combined with patient general condition, think the benefit is&#xD;
             greater than the risks involved in the clinical trials.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  accompanied with other active disease, the treatment is difficult to correct.&#xD;
&#xD;
          -  bacteria, fungus, or virus infection, unable to control.&#xD;
&#xD;
          -  people living with HIV.&#xD;
&#xD;
          -  active hepatitis B virus and hepatitis C virus infection.&#xD;
&#xD;
          -  of pregnancy and nursing mothers.&#xD;
&#xD;
          -  before entering the test of the use of glucocorticoid systemic treatment within a&#xD;
             week.&#xD;
&#xD;
          -  confirmed before used CAR - but invalid patients treated T cells, after in the&#xD;
             physical examination, experts discuss confirmed by a team doesn't fit in the CAR again&#xD;
             - T treatment.Before used gene therapy method.&#xD;
&#xD;
          -  the researchers believe that might increase risk subjects or interfere with the test&#xD;
             results of any situation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huang Jianzhang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Shenzhen immune gene therapy research institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lai Xun, Doctor</last_name>
    <phone>13577096609</phone>
    <email>1729112214@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chang Lung-Ji, Doctor</last_name>
    <phone>13671121909</phone>
    <email>longflorida@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First people's hospital of Yunnan province</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>NCT650000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First People's Hospital of Yunnan</investigator_affiliation>
    <investigator_full_name>Xun Lai</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>4s CAR-T19</keyword>
  <keyword>B cell leukemia</keyword>
  <keyword>B-ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

